The effects of competitive displacement on haloperidol's plasma distribution in normolipidemic and hyperlipidemic plasma

Drug Development and Industrial Pharmacy

Volumn 31, Issue 9, 2005, Pages 901-905

  Procyshyn, Ric M ^a,b   Ho, Tiffany ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b RIVERVIEW HOSPITAL   (Canada)

Author keywords

Cholesterol; Haloperidol; Lipids; Triglycerides

Indexed keywords

HALOPERIDOL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN; WARFARIN;

ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DYSLIPIDEMIA; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IN VITRO STUDY; LIPOPROTEIN BLOOD LEVEL;

ANTICOAGULANTS; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BLOOD PROTEINS; HALOPERIDOL; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; WARFARIN;

EID: 27544467878     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500272058     Document Type: Article

References (15)

1. Brajtburg, J., Elberg, S., Bolard, J., Kobayashi, G. S., Levy, R. A., Jr. Ostlund, R. E., Schlessinger, D., & Medoff, G. (1984). Interaction of plasma proteins and lipoproteins with amphotericin B. Journal of Infectious Diseases, 149, 986-997.
2. Brunner, L. J., Vadiei, K., & Luke, D. R. (1988). Cyclosporine disposition in the hyperlipidemic rat model. Research Communications in Chemical Pathology and Pharmacology, 59, 339-348.
3. Davis, R. A. (1996). Lipoprotein structure and function. In: D. E. Vance (Ed.), Biochemistry of Lipids, Lipoproteins and Membranes. New York: Elsevier, 403-426.
4. Dursun, S. M., Szemis, A., Andrews, H., Reveley, M. A. (1999). The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. Journal of Psychiatry and Neuroscience, 24, 453-455.
5. Lemaire, M., & Tillement, J. P. (1982). Rose of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporine A in the blood. Journal of Pharmacy and Pharmacology, 34, 715-718.
6. Machard, B., Misslin, P., & Lemaire, M. (1989). Influence of plasma protein binding on the brain re-uptake of an antifungal agent, terbinafine, in rats. Journal of Pharmacy and Pharmacology, 41, 700-704.
7. Pande, S., Procyshyn, R. M., Nazerali, M., Attwood, D., Chow, K. (2002). Do triglycerides modulate the effectiveness of clozapine? International Clinical Psychopharmacology, 17, 197-199.
8. Procyshyn, R. M. (2003). Clozapine, triglycerides and clinical effectiveness: a hypothesis. Advances in Pharmacy, 1, 223-227.
9. Procyshyn, R. M., Kennedy, N. B., Marrriage, S., Wasan, K. M. (2001). Plasma protein and lipoprotein distribution of clozapine. American Journal of Psychiatry, 158, 949-951.
10. Procyshyn, R. M., Tsai, G., & Wasan, K. M. (2003). The influence of dyslipidemia on the plasma protein and lipoprotein distribution of haloperidol. European Neuropsychopharmacology, 13, 33-37.
11. Procyshyn, R. M., Ho, T., & Wasan, K. M. (2005), Competitive displacement of clozapine from plasma proteins in normolipidemic and hyperlipidemic plasma samples: the clinical implications. Drug Development and Industrial Pharmacy, 31, 331-337.
12. Wasan, K. M. (1996). Modifications in plasma lipoprotein concentration and lipid composition regulated the biological activity of hydrophobic drugs. Journal of Pharmacological and Toxicological Methods, 36, 1-11.
13. Wasan, K. M., & Cassidy, S. M. (1998). Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. Journal of Pharmaceutical Sciences, 87, 411-424.
14. Wasan, K. M., Vadiei, K., Lopez-Berestein, G., Luke, D. R. (1990). Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. Journal of Infectious Diseases, 161, 562-566.
15. Wasan, K. M., Cassidy, S. M., Ramaswamy, M. et al. (1999). A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cycloporine. Pharmaceutical Research, 16, 165-169.